Tags : LIMT

Eiger Pharmaceuticals Reports Results of Lambda in P-II LIMT (Lambda

Vartika Singh October 18, 2018

Shots: The P-II LIMT study involves assessing of (peg INF-Lambda) Lambda 120/180 μg SC IV qw for 48wks. in ratio (1:1) (N=33) in patients with chronic HDV, testing safety, efficacy […]readmore

Tags : LIMT

Eiger Pharmaceuticals Reports Results of Lambda in P-II LIMT (Lambda

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : LIMT

Eiger Pharmaceuticals Reports Results of Lambda in P-II LIMT (Lambda

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company